View Past PerformanceThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsTyme Technologies バランスシートの健全性財務の健全性 基準チェック /66主要情報0%負債資本比率US$0負債インタレスト・カバレッジ・レシオn/a現金US$77.11mエクイティUS$74.14m負債合計US$6.02m総資産US$80.16m財務の健全性に関する最新情報分析記事 • Aug 05We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Mar 19We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Nov 19Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Jul 19We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Mar 26Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Dec 09Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...すべての更新を表示Recent updatesSeeking Alpha • Sep 15Syros, Tyme Technologies jump more than 20% after hours as shareholders approve mergerShareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.分析記事 • Aug 05We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Jul 05TYME stock surges on merger agreement and Syros PharmaceuticalsDevelopment stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.Seeking Alpha • May 26Tyme Technologies: Net-Net Biopharma Exploring Strategic AlternativesTyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.Recent Insider Transactions Derivative • May 04Co-Founder & Director notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$0.31, it would amount to US$561k. Since June 2021, Steven's direct individual holding has decreased from 23.99m shares to 20.65m. Company insiders have collectively sold US$801k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • May 02Co-Founder & Director notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$0.31, it would amount to US$561k. Since June 2021, Steven's direct individual holding has decreased from 23.99m shares to 20.65m. Company insiders have collectively sold US$800k more than they bought, via options and on-market transactions in the last 12 months.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Richie Cunningham was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Mar 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Richie Cunningham was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Mar 19We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent Insider Transactions Derivative • Feb 03Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 25th of January. If the sale is conducted around the recent share price of US$0.50, it would amount to US$854k. Since March 2021, Steven's direct individual holding has decreased from 24.49m shares to 21.59m. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Feb 01Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 25th of January. If the sale is conducted around the recent share price of US$0.50, it would amount to US$854k. Since March 2021, Steven's direct individual holding has decreased from 24.49m shares to 21.59m. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Dec 07Tyme Technologies Offers Incredible Risk-RewardTyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.分析記事 • Nov 19Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent Insider Transactions Derivative • Nov 01Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 26th of October. If the sale is conducted around the recent share price of US$0.97, it would amount to US$1.4m. Since December 2020, Steven's direct individual holding has decreased from 25.04m shares to 22.52m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Sep 25Independent Director recently bought US$52k worth of stockOn the 22nd of September, David Carberry bought around 50k shares on-market at roughly US$1.03 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$2.0m more in shares than they bought in the last 12 months.Seeking Alpha • Aug 27Tyme Technologies: The Market Missed The Bullish MemoTyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.Recent Insider Transactions Derivative • Jul 29Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Jul 27Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Jul 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Jul 19We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...Recent Insider Transactions Derivative • May 03Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 414k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$1.60, it would amount to US$662k. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 24.32m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Price Target Changed • Apr 03Price target increased to US$9.44Up from US$8.50, the current price target is provided by 1 analyst. New target price is 405% above last closing price of US$1.87. Stock is up 87% over the past year.Executive Departure • Apr 02Chief Medical Officer has left the companyOn the 31st of March, Giuseppe Del Priore's tenure in the role of Chief Medical Officer ended. We don't have any record of a personal shareholding under Giuseppe's name. A total of 2 executives have left over the last 12 months.分析記事 • Mar 26Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Recent Insider Transactions • Feb 21Insider recently sold US$55k worth of stockOn the 16th of February, Michael Demurjian sold around 20k shares on-market at roughly US$2.77 per share. In the last 3 months, there was an even bigger sale from another insider worth US$613k. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.分析記事 • Feb 19Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...Recent Insider Transactions • Feb 19Insider recently sold US$55k worth of stockOn the 16th of February, Michael Demurjian sold around 20k shares on-market at roughly US$2.77 per share. In the last 3 months, there was an even bigger sale from another insider worth US$613k. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.Is New 90 Day High Low • Feb 04New 90-day high: US$3.53The company is up 265% from its price of US$0.97 on 05 November 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 18% over the same period.分析記事 • Feb 02Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...Recent Insider Transactions Derivative • Jan 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 519.00k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of January. If the sale is conducted around the recent share price of US$1.88, it would amount to US$976k. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 24.93m. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.Is New 90 Day High Low • Jan 05New 90-day high: US$1.34The company is up 36% from its price of US$0.98 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Recent Insider Transactions • Dec 16Co-Founder recently sold US$613k worth of stockOn the 14th of December, Steven Hoffman sold around 500k shares on-market at roughly US$1.23 per share. This was the largest sale by an insider in the last 3 months. This was Steven's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Dec 16Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 500.00k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of December. If the sale is conducted around the recent share price of US$1.26, it would amount to US$630k. Since December 2019, Steven's direct individual holding has decreased from 26.49m shares to 25.65m. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Dec 16Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...分析記事 • Dec 09Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...Is New 90 Day High Low • Dec 01New 90-day high: US$1.05The company is up 7.0% from its price of US$0.99 on 01 September 2020. The American market is also up 7.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 27New 90-day low: US$0.92The company is down 23% from its price of US$1.20 on 29 July 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Recent Insider Transactions Derivative • Oct 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 543.00k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of October. If the sale is conducted around the recent share price of US$1.00, it would amount to US$543k. For the year to March 2020, Steven's total compensation was 61% salary and 39% non-salary. Since December 2019, Steven's direct individual holding has decreased from 26.49m shares to 25.95m. Company insiders have collectively sold US$1.1m more than they bought, via options and on-market transactions in the last 12 months.財務状況分析短期負債: TYMEの 短期資産 ( $79.0M ) が 短期負債 ( $5.6M ) を超えています。長期負債: TYMEの短期資産 ( $79.0M ) が 長期負債 ( $400.9K ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: TYMEは負債がありません。負債の削減: TYME 5 年前には負債がありませんでした。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: TYMEは、現在の フリーキャッシュフロー に基づき、3 年以上にわたって十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: TYMEフリーキャッシュフローが毎年18.3 % の歴史的率で減少し続ける場合、3 年以上にわたって十分なキャッシュランウェイを持っています。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/09/16 08:53終値2022/09/16 00:00収益2022/06/30年間収益2022/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tyme Technologies, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Arlinda LeeCanaccord GenuityJoshua SchimmerEvercore ISISwayampakula RamakanthH.C. Wainwright & Co.
分析記事 • Aug 05We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • Mar 19We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Nov 19Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Jul 19We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Mar 26Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Dec 09Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Sep 15Syros, Tyme Technologies jump more than 20% after hours as shareholders approve mergerShareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
分析記事 • Aug 05We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05TYME stock surges on merger agreement and Syros PharmaceuticalsDevelopment stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26Tyme Technologies: Net-Net Biopharma Exploring Strategic AlternativesTyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.
Recent Insider Transactions Derivative • May 04Co-Founder & Director notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$0.31, it would amount to US$561k. Since June 2021, Steven's direct individual holding has decreased from 23.99m shares to 20.65m. Company insiders have collectively sold US$801k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • May 02Co-Founder & Director notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$0.31, it would amount to US$561k. Since June 2021, Steven's direct individual holding has decreased from 23.99m shares to 20.65m. Company insiders have collectively sold US$800k more than they bought, via options and on-market transactions in the last 12 months.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Richie Cunningham was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Mar 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Richie Cunningham was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Mar 19We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recent Insider Transactions Derivative • Feb 03Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 25th of January. If the sale is conducted around the recent share price of US$0.50, it would amount to US$854k. Since March 2021, Steven's direct individual holding has decreased from 24.49m shares to 21.59m. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Feb 01Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 25th of January. If the sale is conducted around the recent share price of US$0.50, it would amount to US$854k. Since March 2021, Steven's direct individual holding has decreased from 24.49m shares to 21.59m. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Dec 07Tyme Technologies Offers Incredible Risk-RewardTyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.
分析記事 • Nov 19Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recent Insider Transactions Derivative • Nov 01Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 26th of October. If the sale is conducted around the recent share price of US$0.97, it would amount to US$1.4m. Since December 2020, Steven's direct individual holding has decreased from 25.04m shares to 22.52m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Sep 25Independent Director recently bought US$52k worth of stockOn the 22nd of September, David Carberry bought around 50k shares on-market at roughly US$1.03 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$2.0m more in shares than they bought in the last 12 months.
Seeking Alpha • Aug 27Tyme Technologies: The Market Missed The Bullish MemoTyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.
Recent Insider Transactions Derivative • Jul 29Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Jul 27Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Jul 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Jul 19We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Recent Insider Transactions Derivative • May 03Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 414k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$1.60, it would amount to US$662k. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 24.32m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Price Target Changed • Apr 03Price target increased to US$9.44Up from US$8.50, the current price target is provided by 1 analyst. New target price is 405% above last closing price of US$1.87. Stock is up 87% over the past year.
Executive Departure • Apr 02Chief Medical Officer has left the companyOn the 31st of March, Giuseppe Del Priore's tenure in the role of Chief Medical Officer ended. We don't have any record of a personal shareholding under Giuseppe's name. A total of 2 executives have left over the last 12 months.
分析記事 • Mar 26Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Recent Insider Transactions • Feb 21Insider recently sold US$55k worth of stockOn the 16th of February, Michael Demurjian sold around 20k shares on-market at roughly US$2.77 per share. In the last 3 months, there was an even bigger sale from another insider worth US$613k. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.
分析記事 • Feb 19Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...
Recent Insider Transactions • Feb 19Insider recently sold US$55k worth of stockOn the 16th of February, Michael Demurjian sold around 20k shares on-market at roughly US$2.77 per share. In the last 3 months, there was an even bigger sale from another insider worth US$613k. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.
Is New 90 Day High Low • Feb 04New 90-day high: US$3.53The company is up 265% from its price of US$0.97 on 05 November 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 18% over the same period.
分析記事 • Feb 02Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...
Recent Insider Transactions Derivative • Jan 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 519.00k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of January. If the sale is conducted around the recent share price of US$1.88, it would amount to US$976k. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 24.93m. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.
Is New 90 Day High Low • Jan 05New 90-day high: US$1.34The company is up 36% from its price of US$0.98 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Recent Insider Transactions • Dec 16Co-Founder recently sold US$613k worth of stockOn the 14th of December, Steven Hoffman sold around 500k shares on-market at roughly US$1.23 per share. This was the largest sale by an insider in the last 3 months. This was Steven's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Dec 16Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 500.00k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of December. If the sale is conducted around the recent share price of US$1.26, it would amount to US$630k. Since December 2019, Steven's direct individual holding has decreased from 26.49m shares to 25.65m. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Dec 16Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...
分析記事 • Dec 09Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
Is New 90 Day High Low • Dec 01New 90-day high: US$1.05The company is up 7.0% from its price of US$0.99 on 01 September 2020. The American market is also up 7.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 27New 90-day low: US$0.92The company is down 23% from its price of US$1.20 on 29 July 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Recent Insider Transactions Derivative • Oct 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 543.00k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of October. If the sale is conducted around the recent share price of US$1.00, it would amount to US$543k. For the year to March 2020, Steven's total compensation was 61% salary and 39% non-salary. Since December 2019, Steven's direct individual holding has decreased from 26.49m shares to 25.95m. Company insiders have collectively sold US$1.1m more than they bought, via options and on-market transactions in the last 12 months.